Редактирование: MBTD1 (раздел)

==Publications==

{{medline-entry
|title=LncRNA [[TTN]]-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/[[MBTD1]] axis.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/31600142
|abstract=To explore the mechanism by which long non-coding RNA (lncRNA) [[TTN]]-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the microRNA miR-134-5p/malignant brain tumour domain containing 1 ([[MBTD1]]) axis. The lncRNA [[TTN]]-AS1 was highly expressed in osteosarcoma and was associated with poor prognosis. The lncRNA [[TTN]]-AS1 promoted cell viability and inhibited apoptosis. MiR-134-5p targeted [[MBTD1]], which was regulated by lncRNA [[TTN]]-AS1. [[MBTD1]] was highly expressed in osteosarcoma and was associated with poor prognosis. [[MBTD1]] promoted cell viability and inhibited apoptosis, and knockdown of [[MBTD1]] reversed the cancer-promoting effects of lncRNA [[TTN]]-AS1. Downregulation of lncRNA [[TTN]]-AS1 reduced drug resistance. In osteosarcoma, lncRNA [[TTN]]-AS1 promoted the expression of [[MBTD1]] by targeting miR-134-5p and regulated cell growth, apoptosis and drug resistance. The expression characteristics of genes in osteosarcoma patients were analysed using bioinformatics. Plasmid transfection technology was applied to silence or overexpress lncRNA [[TTN]]-AS1, miR-134-5p and [[MBTD1]]. Western blotting and quantitative polymerase chain reaction (qPCR) were used to detect protein and RNA, respectively. A cell counting kit 8 (CCK-8) and flow cytometry were used to detect cell viability and apoptosis. The effects of lncRNA [[TTN]]-AS1 and [[MBTD1]] on osteosarcoma in vivo were studied by using a tumour burden assay.
|mesh-terms=* Aging
* Apoptosis
* Brain Neoplasms
* Cell Line, Tumor
* Cell Proliferation
* Chromosomal Proteins, Non-Histone
* Computational Biology
* Drug Resistance
* Gene Expression Regulation, Neoplastic
* Humans
* MicroRNAs
* Osteosarcoma
* RNA, Long Noncoding
|keywords=* aging and age-related diseases
* lncRNA TTN-AS1
* malignant brain tumour domain containing protein 1
* miR-134-5p
* osteosarcoma
* resistance
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814585
}}